|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Douglas C. Bryant||Chairman & CEO||1,41M||S.O.||1958|
|Mr. Robert J. Bujarski J.D.||Pres & COO||770,62k||S.O.||1969|
|Ms. Michelle A. Hodges||Gen. Counsel||620,61k||S.O.||1960|
|Dr. Werner Kroll Ph.D.||Sr. VP of R&D||758,22k||2,1M||1957|
|Mr. Joseph M. Busky CPA||Chief Financial Officer||S.O.||S.O.||1968|
|Ruben Argueta||Director of Investor Relations||S.O.||S.O.||S.O.|
|Mr. Michael S. Iskra||Chief Commercial Officer||S.O.||S.O.||1970|
|Phillip S. Askim||VP, Associate Gen. Counsel & Sec.||S.O.||S.O.||S.O.|
|Dr. Johannes Kehle||Pres of AnDiaTec Division||S.O.||S.O.||S.O.|
|Mr. Rhys de Callier||VP of Strategy & Portfolio Management||S.O.||S.O.||S.O.|
QuidelOrtho Corporation provides various in vitro diagnostics products worldwide. The company's product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and clinical and at-home products to detect COVID-19. It provides visually-read lateral flow products in infectious disease and reproductive health; direct fluorescent antibodies in infectious disease and virology; micro-titer production with a focus on bone and complement pathway markets; fluorescent immunoassay products; molecular diagnostic products comprising Savanna, an integrated molecular diagnostic system; immunodiagnostics, clinical chemistry, and integrated testing systems to serve diagnostic labs of all sizes; immunodiagnostic donor screening systems and services that drive blood safety; pre-transfusion testing that automates blood bank workload with software to standardize operations, simplify tasks, and improve productivity; and Ortho Care services and informatics products. The company was founded in 1979 and is headquartered in San Diego, California.
L’ISS Governance QualityScore de QuidelOrtho Corporation en date du 1 juillet 2022 est 4. Les scores principaux sont Audit : 8; Société : 3; Droits des actionnaires : 3; Compensation : 4.